Startup Alzheon revives tramiprosate for Alzheimer's with license for prodrug
This article was originally published in Scrip
Executive Summary
Lexington, Massachusetts-based startup Alzheon raised an undisclosed amount of private capital from two unidentified private investors to develop ALZ-801, a prodrug of the well-known Alzheimer's drug tramiprosate (Alzhemed), which failed in Phase III clinical trials.